Aerovate Therapeutics(AVTE) - 2023 Q4 - Annual Results

Exhibit 99.1 Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights ● Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) ● Completed enrollment in the Phase 2b portion and enrolled first patient into the Phase 3 portion of the IMPAHCT trial of AV-101 in November 2023 ● Expanded intellectual property portfolio with two issued patents in 2023 ● Board of Directors ex ...